IL17A and psoriatic arthritis: In patients with psoriatic arthritis, bimekizumab treatment neutralizes IL-17A and IL-17F greatly inhibits pro-inflammatory cytokine secretion, but IL-17A blockade in IBD patients induced high risk of severe adverse events in clinical trials (12, 13), indicating a protective role of IL-17A in IBD.